InsidersTradesSigma
GBS Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the GBS Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, GBS Inc. has published 44 reports. The latest transaction was reported on 12 October 2022 (Attribution). Among the most active insiders: Life Science Biosensor Diagnostics Pty Ltd. All data is accessible without an account.
44
Insider Decl.
0
Thresholds
€68,672
8 ops.
Buy Volume
€6m
29 ops.
Sell Volume
37Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 12 October 2022
Declarations44 total
15,000 shares0Common Stock, par value $0.01 per shareSEC:0001493152-22-028191:0
75,000 shares0Common Stock, par value $0.01 per shareSEC:0001493152-22-028185:0
15,000 shares0Common Stock, par value $0.01 per shareSEC:0001493152-22-028193:0
15,000 shares0Common Stock, par value $0.01 per shareSEC:0001493152-22-028190:0
75,000 shares0Common Stock, par value $0.01 per shareSEC:0001493152-22-028189:0
15,000 shares0Common Stock, par value $0.01 per shareSEC:0001493152-22-028194:0
80,000 shares0Common Stock, par value $0.01 per shareSEC:0001493152-22-028196:0
5,000 shares@ US$0.64984.0% of flowCommon StockSEC:0001493152-22-017644:0
Ideal exit: 19 Mar 2023 (T+270)
15,970 shares@ US$0.611511.9% of flowCommon StockSEC:0001493152-22-017447:0
Ideal exit: 14 Mar 2023 (T+270)
576,028 shares@ US$0.514.4% of flowCommon StockSEC:0001493152-22-005162:0
100,000 shares@ US$0.630.9% of flowCommon StockSEC:0001493152-22-005003:0
100,000 shares@ US$0.751.1% of flowCommon StockSEC:0001493152-22-004901:0
100,000 shares@ US$0.841.3% of flowCommon StockSEC:0001493152-22-004631:0
100,000 shares@ US$0.861.3% of flowCommon StockSEC:0001493152-22-004114:0
100,000 shares@ US$0.891.3% of flowCommon StockSEC:0001493152-22-003841:0
100,000 shares@ US$0.921.4% of flowCommon StockSEC:0001493152-22-003521:0
100,000 shares@ US$0.901.4% of flowCommon StockSEC:0001493152-22-003048:0
100,000 shares@ US$1.001.5% of flowCommon StockSEC:0001493152-22-002933:0
100,000 shares@ US$0.921.4% of flowCommon StockSEC:0001493152-22-002935:0
4,500 shares@ US$1.5538.1% of flowCommon stockSEC:0001493152-22-000016:0
Ideal exit: 26 Sept 2022 (T+270)
200,000 shares@ US$1.494.5% of flowCommon StockSEC:0001493152-21-032217:0
2,800 shares@ US$1.6926.0% of flowCommon stockSEC:0001493152-21-032097:0
Ideal exit: 12 Sept 2022 (T+270)
10,000 shares@ US$1.7019.3% of flowCommon StockSEC:0001493152-21-030681:0
Ideal exit: 2 Sept 2022 (T+270)
250,000 shares@ US$1.877.1% of flowCommon StockSEC:0001493152-21-030491:0
100,000 shares@ US$1.68812.6% of flowCommon StockSEC:0001493152-21-030239:0
25 of 44 declarations
About GBS Inc.
GBS Inc. is a biosensor and diagnostic technology company listed in the United States on the NASDAQ market, with headquarters in New York, New York, United States. The company was incorporated in Delaware on December 5, 2016, following operating roots that began in 2016 through related entities in Australia and the Asia-Pacific region. Its core investment case has historically been built around non-invasive diagnostic innovation, with a particular emphasis on making diabetes monitoring easier, less painful, and more convenient for patients. At the center of GBS Inc.’s business is its biosensor platform and the flagship Saliva Glucose Biosensor (SGB) program, together with the associated software and digital information system. The company’s stated goal is to offer a saliva-based alternative to conventional finger-prick glucose testing, positioning itself around a patient-friendly, non-invasive user experience. Beyond this initial use case, management has described a broader platform strategy spanning multiple diagnostic modalities, including biochemistry, immunology, tumor markers, hormones, and nucleic-acid-based testing. The company has also worked on SARS-CoV-2-related testing initiatives. Operationally, GBS Inc. has relied on clinical and academic collaborations to support product development and validation. The company has highlighted clinical studies in the United States and broader efforts to advance manufacturing capabilities, including work linked to Australia and university-associated buildout initiatives. That profile suggests a business still heavily weighted toward R&D and pre-commercial execution, with future value creation dependent on regulatory progress, manufacturing readiness, and successful market adoption. From a competitive standpoint, GBS operates in a demanding diagnostic landscape dominated by established players in medical devices, in vitro diagnostics, and diabetes monitoring. Its differentiation lies in the conceptual appeal of saliva-based testing and the potential advantages of convenience, reduced pain, and repeatability. However, as with many early-stage medtech names, the company faces meaningful execution risk, including funding needs, clinical validation hurdles, reimbursement uncertainty, and commercialization delays. Recent milestones have centered on continued platform development, clinical work, and manufacturing planning. For French-speaking investors, GBS Inc. should be viewed as a small-cap health-tech name on NASDAQ in the United States, with a high-risk/high-upside profile tied to the company’s ability to translate a promising diagnostic concept into a scalable commercial business.
